Novartis contends Roche ‘unjustly enriched’ itself with $210 mln in fees – lawsuit
June 29, 2021; 11:18 AM EDT
(Reuters; John Miller)
ZURICH, June 29 (Reuters) – Novartis AG (NOVN.S) wants Roche Holding AG (ROG.S) to return $210 million after accusing its Swiss rival of inappropriately pocketing fees from a 16-year-old patent licensing agreement, according to a lawsuit in U.S. District Court.
The dispute, launched by Novartis in a California state court but recently shifted to a federal court, stems from a 2005 deal requiring U.S.-based Chiron Corp to make payments to Roche’s U.S. Genentech unit for use of its intellectual property.
In 2006, Novartis bought Chiron, a maker of biological drugs and vaccines, and continued making the payments to Roche as it developed products like inflammation drug Ilaris, with revenue of roughly $900 million annually, and psoriasis drug Cosentyx, Novartis’s current top seller at around $4 billion annually.
“Novartis subsequently discovered that it mistakenly overpaid,” Novartis lawyers wrote in a heavily redacted complaint published last Thursday in the U.S. District Court in California.
“Genentech was aware or should have been aware that Novartis had overpaid … to Genentech throughout the term of the Agreement,” Novartis lawyers wrote. “By mistake, Novartis overpaid … to Genentech on its drug products, Ilaris and Cosentyx, to which Genentech was not entitled.”
Roche has long owned lucrative patents needed by other companies to make biological drugs like monoclonal antibodies, including the so-called “Cabilly patents” that reaped billions of dollars in royalties over the years for the Swiss company before finally expiring three years ago.
Roche on Tuesday said it has a policy of not commenting on pending litigation.
Since it discovered what it alleges is an overpayment, Novartis said it has been trying to get Roche to return the money, to no avail.
“Genentech has been unjustly enriched at Novartis’s expense,” Novartis lawyers wrote.
Our Standards: The Thomson Reuters Trust Principles.